Alpha Tau Medical Ltd. files 20-F

Alpha Tau Medical Ltd. reported a net loss of $42,627 for the fiscal year ended December 31, 2025, an increase from $31,750 in 2024, as the company continues to invest heavily in research and development of its Alpha DaRT technology for solid tumors. The company secured approximately $45.5 million in net proceeds from equity issuances in 2025 to fund its operations and growth strategy.